USA-based clinical-stage biotechnology company Pfenex Inc. is saying goodbye to its Chief Financial Officer, Dr. Paul Wagner, who has been said on Friday to leaving the Company by October 13, 2017. Pfenex said it was seeking a replacement CFO.
Additionally, Steve Sandoval, Chief Manufacturing Officer, is leaving the Company effective September 8, 2017. He will continue supporting the company as a consultant through the first quarter of 2018 to further assist in the transition.
Eef Schimmelpennink, CEO said: “We all wish Paul and Steve all the best in their new endeavors. I look forward to working with Paul through the transition.”
Dr. Wagner said: “My time at Pfenex has been rewarding. I have been particularly honored to have helped build the company alongside Pfenex’s many dedicated employees. I am confident that Eef and the Pfenex team’s focus and capability will help drive success and build value for our shareholders and I wish them great success.”